Internationalism No. 73, March 2025 Page 14 From the series Industry and pharmaceuticals The surge in China’s biopharmaceutical industry over the last decade is part of its broader scientific and technological ascent and therefore deserves our attention. Such growth presents a challenge to other imperialist powers. The Biosecure Act’s intention, to reduce the ties between American and Chinese biotech firms, has been branded by The Economist as “old-fashioned protectionism”. The British weekly recognises, however, that the clash goes well beyond a trade war. The stakes are higher. In a lengthy cover story [“The rise of Chinese science”], it writes that “China is now a leading scientific power”. Just five years ago, this was still considered only a possibility. The current question is whether this is “welcome or worrying” [June 15th, 2024]. Unity and scission The viewpoint of that publication, an authoritative voice of one of the power-houses of imperia...